相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2020)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)
Joel M. Gelfand et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Atul Deodhar et al.
LANCET (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis
Therezia Bokor-Billmann et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2019)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
Stefan Schreiber et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Risankizumab: First Global Approval
Kate McKeage et al.
DRUGS (2019)
1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease
Bruce E. Sands et al.
GASTROENTEROLOGY (2019)
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
Craig A. Elmets et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
Mamitaro Ohtsuki et al.
JOURNAL OF DERMATOLOGY (2019)
Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report
Matthew K. Smith et al.
BMC GASTROENTEROLOGY (2019)
Bedside to bench: defining the immunopathogenesis of psoriatic arthritis
Arlene Bravo et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
IL-23 in inflammatory bowel diseases and colon cancer
Markus F. Neurath
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities
James G. Krueger et al.
EXPERIMENTAL DERMATOLOGY (2018)
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis
Lluis Puig
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Safety of biologics in psoriasis
Masahiro Kamata et al.
JOURNAL OF DERMATOLOGY (2018)
Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly
Sofie Mylle et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2018)
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
C. Ryan et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers A Randomized Placebo-Controlled Trial
Nehal N. Mehta et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2018)
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
Marie-Astrid Boutet et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Scanning the Immunopathogenesis of Psoriasis
Andrea Chiricozzi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis
Jawad Bilal et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
New treatment options for inflammatory bowel diseases
Bram Verstockt et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A
Yumeng Li et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
2018 Eastern Regional Meeting
JOURNAL OF INVESTIGATIVE MEDICINE (2018)
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
Craig Leonardi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies
Jorge R. Georgakopoulos et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A. Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison
Joy Feld et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions A Secondary Analysis of 2 Randomized Clinical Trials
Peter Foley et al.
JAMA DERMATOLOGY (2018)
A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It
Nicola Tamassia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment
Tom C. Chan et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon et al.
LANCET (2018)
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
Todd Wechter et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Brian G. Feagan et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes
Judilyn Fuentes-Duculan et al.
EXPERIMENTAL DERMATOLOGY (2017)
The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
Zenas Z. N. Yiu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
The role of IL 23 in the treatment of psoriasis
Lluis Puig
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2017)
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases
Clara Abraham et al.
GASTROENTEROLOGY (2017)
Prevalence and Phenotype of Concurrent Psoriasis and Inflammatory Bowel Disease
Hester Eppinga et al.
INFLAMMATORY BOWEL DISEASES (2017)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing αβ T cell clones
Tiago R. Matos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Psoriasis and comorbid diseases Epidemiology
Junko Takeshita et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
A. Menter et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases
Taku Kuwabara et al.
MEDIATORS OF INFLAMMATION (2017)
Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
Michael Roman et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
An update on psoriasis and metabolic syndrome: A meta-analysis of observational studies
Sanminder Singh et al.
PLOS ONE (2017)
Targeting IL-17 in psoriatic arthritis
Elizabeth A. Wang et al.
EUROPEAN JOURNAL OF RHEUMATOLOGY (2017)
Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin
B. Dyring-Andersen et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Mechanistic rationales for targeting interleukin-17A in spondyloarthritis
Siba P. Raychaudhuri et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders
Salvatore D'Angelo et al.
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS (2017)
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris
A. Chiricozzi et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment
H. Jethwa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2016)
Update on psoriasis immunopathogenesis and targeted immunotherapy
Satveer K. Mahil et al.
SEMINARS IN IMMUNOPATHOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease
Stephan R. Targan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Targeting the interleukin-23/17 axis in axial spondyloarthritis
Ananta Paine et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes
Bobbak Mansouri et al.
JAMA DERMATOLOGY (2016)
Interleukin 6 regulates psoriasiform inflammation-associated thrombosis
Yunmei Wang et al.
JCI INSIGHT (2016)
Inflammation, Immunity, and Hypertensive End-Organ Damage
William G. McMaster et al.
CIRCULATION RESEARCH (2015)
Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis
Evan L. Siegel et al.
CURRENT OPINION IN RHEUMATOLOGY (2015)
Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin
Francesca Prignano et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2015)
An autoimmune attack on melanocytes triggers psoriasis and cellular hyperplasia
James G. Krueger
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Psoriatic Inflammation Facilitates the Onset of Arthritis in a Mouse Model
Mayuko Yamamoto et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Angiogenesis and lymphangiogenesis in inflammatory skin disorders
Gilda Varricchi et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Christopher E. M. Griffiths et al.
LANCET (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
M. Lebwohl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis
Iannis E. Adamopoulos et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Crosstalk among IL-23 and DNAX Activating Protein of 12 kDa-Dependent Pathways Promotes Osteoclastogenesis
Hyun-Seock Shin et al.
JOURNAL OF IMMUNOLOGY (2015)
IL-17 and Th17 Cells in Atherosclerosis Subtle and Contextual Roles
Soraya Taleb et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities
Julia Shlyankevich et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Immunology of Psoriasis
Michelle A. Lowes et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 32 (2014)
The IL-23/IL-17 axis in psoriatic arthritis
Erika Suzuki et al.
AUTOIMMUNITY REVIEWS (2014)
Cellular sources of IL-17 in psoriasis: a paradigm shift?
Romy R. M. C. Keijsers et al.
EXPERIMENTAL DERMATOLOGY (2014)
Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?
Andrea Chiricozzi et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2014)
Proatherogenic Conditions Promote Autoimmune T Helper 17 Cell Responses In Vivo
Hoyong Lim et al.
IMMUNITY (2014)
Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
Stanley Cheuk et al.
JOURNAL OF IMMUNOLOGY (2014)
In Vivo Induction of Cutaneous Inflammation Results in the Accumulation of Extracellular Trap-Forming Neutrophils Expressing RORγt and IL-17
Romy R. M. C. Keijsers et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Psoriasis prevalence among adults in the United States
Tara D. Rachakonda et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Interleukin-23/Interleukin-17 Axis in Spondyloarthritis Pathogenesis Th17 and Beyond
Judith A. Smith et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
Andrew Johnston et al.
JOURNAL OF IMMUNOLOGY (2013)
The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
David A. Martin et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics
Philip J. Mease et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2013)
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
Nehal N. Mehta et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Modulation of Epidermal Transcription Circuits in Psoriasis: New Links between Inflammation and Hyperproliferation
William R. Swindell et al.
PLOS ONE (2013)
Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies
Ehrin J. Armstrong et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
James G. Krueger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Chronic Skin-Specific Inflammation Promotes Vascular Inflammation and Thrombosis
Yunmei Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
IL-17 receptor and its functional significance in psoriatic arthritis
Siba P. Raychaudhuri et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2012)
Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines
M. Lienhard Schmitz et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis
April W. Armstrong et al.
EXPERIMENTAL DERMATOLOGY (2011)
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Yihua Cai et al.
IMMUNITY (2011)
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Andrew M. Lin et al.
JOURNAL OF IMMUNOLOGY (2011)
Gone but Not Forgotten: Lesional Memory in Psoriatic Skin
Rachael A. Clark
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis
Andrea Chiricozzi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
The Emergence of Th17 Cells as Effectors of Renal Injury
A. Richard Kitching et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Structure and function of interleukin-17 family cytokines
Xiaoping Zhang et al.
PROTEIN & CELL (2011)
Interleukin-17-Dependent Autoimmunity to Collagen Type V in Atherosclerosis
Melanie L. Dart et al.
CIRCULATION RESEARCH (2010)
Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database
Nehal N. Mehta et al.
EUROPEAN HEART JOURNAL (2010)
Interleukin 17 Promotes Angiotensin II-Induced Hypertension and Vascular Dysfunction
Meena S. Madhur et al.
HYPERTENSION (2010)
Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
Batya B. Davidovici et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Interleukin-17A upregulates receptor activator of NF-kappa B on osteoclast precursors
Iannis E. Adamopoulos et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes
Lisa C. Zaba et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
AP-1 Activated by Toll-like Receptors Regulates Expression of IL-23 p19
Weicheng Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
IL-17 Induces Osteoclastogenesis From Human Monocytes Alone in the Absence of Osteoblasts, Which Is Potently Inhibited by Anti-TNF-α Antibody: A Novel Mechanism of Osteoclastogenesis by IL-17
Toru Yago et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
The IL-23/Th17 Axis Contributes to Renal Injury in Experimental Glomerulonephritis
Hans-Joachim Paust et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics
Alice Gottlieb et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes
Michele Cargill et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis
Jason R. Chan et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
分享论文
